-

Confluent Medical Sees Dramatic Improvements Around Supply Chain Visibility and Efficiency

Kinaxis empowers medical technology company to get products in the hands of patients faster

OTTAWA, Ontario--(BUSINESS WIRE)--Confluent Medical, a leading materials science, development and manufacturing partner to medical device manufacturers (“OEMs”), has experienced significant improvements to its end-to-end supply chain with Kinaxis. The medical technology (medtech) innovator, that delivers life-saving implants, minimally invasive delivery systems and other medical devices, deployed Kinaxis® in August 2023 with the help of Genpact and credits increased visibility and efficiency to the partnership.

The company specializes in the design, development and large-scale manufacturing of catheter-based devices and Nitinol components – a specialized metal alloy with super-elasticity and shape memory. With 8 facilities across the United States and Costa Rica, 2,000 employees and a wide range of products including complex catheters, high-precision polymer tubing and implantable textiles, the ability to react to any changes in any part of their supply chain quickly was paramount.

Jeff McCoun, vice president, global supply chain at Confluent Medical said, “We had a demand peak that nearly doubled and normally it would have taken months to re-sync our supply chain, but we did it in just weeks. Before Kinaxis, we were running separate spreadsheets for every part of the chain, no one was ever on the same page and if a change happened somewhere, it was never clear to anyone else in the chain. I’ve used other solutions over the course of my career, but I’ve never witnessed as fast and efficient a deployment and improvement as what we’ve seen with Kinaxis.”

Claire Rychlewski, executive vice president, global field sales at Kinaxis said, “Making this type of impact is what drives us. Confluent’s vision is to improve lives by delivering world-class medical devices through innovative material science, engineering, and manufacturing, and we are thrilled to be helping them do that. That’s a big win for all of us.”

Genpact began the Confluent Medical solution design in late 2022 and roll out to more sites and more users is already underway.

Kinaxis works with some of the biggest brands in the world across all sectors including CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end-to-end from strategic planning to last-mile delivery.

About Kinaxis

Kinaxis is the global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit Kinaxis.com or follow us on LinkedIn.

About Confluent Medical

Confluent Applies Materials Science to MedTech Innovation. Confluent specializes in the expert design, development, and large-scale manufacturing of interventional catheter-based devices and implants. Customers rely on Confluent’s expertise in Nitinol material and components, balloon and complex catheters, high-precision polymer tubing, and implantable textiles. With facilities in Fremont and Orange County, California; Warwick, Rhode Island; Windham, Maine; Austin, Texas; Chattanooga, Tennessee; and San Jose, Costa Rica, Confluent has earned the confidence of the leaders in the medical device community through a proven track record of innovative materials science, engineering, and manufacturing. For more information, visit confluentmedical.com.

About Genpact

Genpact (NYSE: G) is a global professional services firm delivering the outcomes that transform our clients' businesses and shape their future. We're guided by our real-world experience redesigning and running thousands of processes for hundreds of global companies. Our clients – including many in the Global Fortune 500 – partner with us for our unique ability to combine deep industry and functional expertise, leading talent, and proven methodologies to drive collaborative innovation that turns insights into action and delivers outcomes at scale. We create lasting competitive advantages for our clients and their customers, running digitally enabled operations and applying our Data-Tech-AI services to design, build, and transform their businesses. And we do it all with purpose. From New York to New Delhi and more than 30 countries in between, our 115,000+ team is passionate in its relentless pursuit of a world that works better for people. Get to know us at Genpact.com and on LinkedIn, Twitter, YouTube, and Facebook.

Contacts

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
289-552-4640

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

Kinaxis Inc.

TSX:KXS


Contacts

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
289-552-4640

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

Social Media Profiles
More News From Kinaxis Inc.

Kinaxis Introduces Maestro Agent Studio, Unlocking Next Level Decision Making Through Composable AI Agents

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX: KXS), the leader in supply chain orchestration, today announced Maestro Agent Studio, making the next phase of its AI agent strategy available to customers following the launch of prebuilt Maestro Agents. Maestro Agent Studio gives supply chain teams a no-code way to compose AI agents grounded in their real operating context, using the same data, workflows, and tools planners already rely on, so agents drive real-world outcomes. Built into t...

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 2026

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial resu...

Kinaxis Announces Intention to Maximize Size of Normal Course Issuer Bid

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that it intends to amend its current normal course issuer bid (the “NCIB”) to increase the number of its common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to approximately 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, which is the maximum allowable un...
Back to Newsroom